SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION)
Sionna Therapeutics shares lost roughly $40 per share after SION-719 Phase 2a readout, cutting the stock by about 90%. Levi & Korsinsky is investigating potential securities law violations on behalf of investors who lost money.
Roughly 90% of Sionna Therapeutics (SION) market value was erased after the Company released Phase 2a PreciSION CF results for SION-719, representing a decline of approximately $40 per share from the stock’s recent trading levels. If you held SION shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The impact on shareholders was driven by the clinical readout. SION-719, when added to standard of care, produced a placebo-adjusted sweat chloride change of -1.0 mmol/L, with a p-value of 0.7. Sionna stated it would not advance SION-719 as an add-on therapy.
The loss was not tied to an apparent liquidity shortfall. Sionna reported approximately $268.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, and a second-quarter 2026 net loss of $29.9 million, with cash expected to fund operations into 2028. Shares nonetheless traded in the mid-$40s as recently as July 2026 before the readout.
